OKYO (OKYO Pharma) Tariff Resilience Score: 5/10 (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OKYO OKYO Pharma Ltd OKYO
23 GF Score
Price $1.34
! 3 Warning Signs
View Full Analysis

What is OKYO Pharma Tariff Resilience Score?

OKYO Pharma OKYO -9.45% 23 Tariff Resilience Score is 5 as of Jul. 16, 2026. GuruFocus rates OKYO with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 1,370 Biotechnology companies, OKYO Pharma ranks better than 62.41% on this metric.

OKYO Pharma has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

OKYO Pharma has Pharmaceutical company with global supply chains. Vulnerable to tariffs on raw materials and finished products, but can leverage alternative suppliers and pricing strategies.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes OKYO Pharma might have Average Resilient.

OKYO Pharma  (NAS:OKYO) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

OKYO Pharma Tariff Resilience Score Related Terms

OKYO vs ENTX, HRTX, RANI: Tariff Resilience Score Comparison

For the Biotechnology subindustry, OKYO Pharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OKYO Pharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OKYO Pharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where OKYO Pharma's Tariff Resilience Score falls into.


OKYO
23GF Score
OKYO Pharma Ltd OKYO
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
OKYO Pharma (OKYO) has a Tariff Resilience Score of 5 as of Jul. 16, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, OKYO Pharma ranks #515 out of 1370 companies in the Biotechnology industry, placing it in the top 37.6%.
Is OKYO Pharma's Tariff Resilience Score too high?
OKYO Pharma's current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. OKYO Pharma's value of 5 is 25% above this industry median. Based on the distribution chart, OKYO Pharma ranks #515 out of 1370 companies in the Biotechnology industry, which is above the industry midpoint. Overall, OKYO Pharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does OKYO Pharma's Tariff Resilience Score compare to ENTX and HRTX?
According to the Biotechnology industry distribution chart, OKYO Pharma ranks #515 out of 1370 companies for Tariff Resilience Score. This puts OKYO Pharma in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. OKYO Pharma's value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OKYO Pharma's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OKYO Pharma's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OKYO Pharma stock overvalued right now?
OKYO Pharma (OKYO) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. OKYO Pharma's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For OKYO Pharma (OKYO), the current Tariff Resilience Score is 5 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OKYO Pharma Business Description

Address 14/15 Conduit Street, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
23GF Score

Get the complete analysis for OKYO

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.34
Price